Scientific Journal for Publishing in Health Research and Technology

Volume 2, Issue 2, 2026, Pages: 93-101

Journal homepage: https://sjphrt.com.ly/index.php/sjphrt/en/index

The Synergistic Impact of Rapid Diagnostic Testing and Antimicrobial Stewardship on Clinical Outcomes: A Comprehensive Review

Dr. Fatma Ibrahim Salama *
Higher Institute for Medical Sciences and Technology/ Msellata, Libya

الأثر التآزري للاختبارات التشخيصية السريعة والإشراف على استخدام المضادات الحيوية على النتائج السريرية: مراجعة شاملة

د. فاطمة إبراهيم سلامة *
المعهد العالي للعلوم الطبية والتقنية- مسلاته، ليبيا

*Corresponding author: dr.Fatmasalama@gmail.com

Received: March 18, 2026	Accepted: April 10, 2026	Published: April 27, 2026

Abstract:
Rapid diagnostic testing (RDT) in conjunction with robust antimicrobial stewardship programs (ASP) represents a transformative approach in clinical microbiology, significantly improving patient outcomes and optimizing antibiotic utilization. This paper reviews advancements in RDT technologies, including Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS), nucleic acid amplification tests (NAATs), and rapid phenotypic antimicrobial susceptibility testing (rAST). Evidence from recent systematic reviews and network meta-analyses demonstrates that this combined strategy leads to a notable reduction in patient mortality, with an odds ratio of 0.72 compared to conventional methods. Furthermore, the integration of RDT and ASP results in a decreased length of hospital stay and a substantial shortening of the time to optimal antimicrobial therapy by nearly 30 hours. The role of medical laboratory professionals is pivotal in this paradigm, encompassing timely reporting, expert interpretation, and diagnostic stewardship. Despite challenges such as initial implementation costs and the need for workflow integration, emerging directions like point-of-care testing and artificial intelligence offer promising avenues for further enhancing infectious disease management. Ultimately, the synergy between rapid diagnostics and proactive stewardship is essential for combating antimicrobial resistance and enhancing the efficiency of global healthcare systems.

Keywords: Rapid Diagnostic Testing, Antimicrobial Stewardship, MALDI-TOF MS, Clinical Outcomes, Antimicrobial Resistance, Bloodstream Infections.

الملخص
يمثل الاختبار التشخيصي السريع (RDT) المقترن ببرامج قوية للإشراف على استخدام المضادات الحيوية (ASP) نهجاً تحولياً في علم الأحياء الدقيقة السريري، مما يحسن نتائج المرضى بشكل كبير ويحسن

استخدام المضادات الحيوية. تستعرض هذه الورقة التقدم في تقنيات التشخيص السريع، بما في ذلك مطيافية الكتلة (MALDI-TOF MS)، واختبارات تضخيم الحمض النووي (NAATs)، واختبار الحساسية للمضادات الحيوية المظهري السريع (rAST). وتظهر الأدلة من المراجعات المنهجية الحديثة والتحليلات التلوية أن هذه الاستراتيجية المشتركة تؤدي إلى انخفاض ملحوظ في وفيات المرضى، بنسبة أرجحية قدرها 0.72 مقارنة بالطرق التقليدية. علاوة على ذلك، يؤدي التكامل بين التشخيص السريع وبرامج الإشراف إلى تقليل مدة الإقامة في المستشفى وتقصير وقت الوصول إلى العلاج الأمثل للميكروبات بنحو 30 ساعة. ويعد دور أخصائيي المختبرات الطبية محورياً في هذا النموذج، حيث يشمل التقارير في الوقت المناسب، والتفسير الخبير، والإشراف التشخيصي. وعلى الرغم من التحديات مثل تكاليف التنفيذ الأولية والحاجة إلى دمج سير العمل، فإن الاتجاهات الناشئة مثل اختبارات نقطة الرعاية والذكاء الاصطناعي توفر طرقاً واعدة لتعزيز إدارة الأمراض المعدية. في الختام، يعد التآزر بين التشخيص السريع والإشراف الاستباقي أمراً ضرورياً لمكافحة مقاومة المضادات الحيوية وتعزيز كفاءة نظم الرعاية الصحية العالمية.

الكلمات المفتاحية: الاختبارات التشخيصية السريعة، الإشراف على المضادات الحيوية، MALDI-TOF MS، النتائج السريرية، مقاومة المضادات الحيوية، عدوى مجرى الدم.

Introduction

Bloodstream infections (BSIs) represent a critical global health concern, characterized by high rates of morbidity, mortality, and substantial healthcare costs [1, 2]. The urgency of accurate and timely pathogen identification, coupled with comprehensive antimicrobial susceptibility profiling, is paramount for effective patient management and for mitigating the escalating threat of antimicrobial resistance (AMR) [3]. Conventional culture-based diagnostic methods, while historically foundational, are often time-consuming, requiring 48 to 72 hours or even longer to yield definitive results. This inherent delay frequently necessitates the empirical administration of broad-spectrum antibiotics, a practice that not only contributes to the emergence and spread of AMR but also can lead to suboptimal patient outcomes, increased toxicity, and prolonged hospital stays [4, 5].

The advent of rapid diagnostic testing (RDT) technologies has heralded a transformative era in clinical microbiology. These innovative methods offer the potential for significantly accelerated pathogen identification and resistance marker detection, thereby enabling earlier initiation of targeted, appropriate antimicrobial therapy [6]. However, the mere availability of rapid results does not inherently guarantee improved clinical outcomes. The effective interpretation, communication, and application of RDT results necessitate a robust, well-structured, and proactive antimicrobial stewardship program (ASP). ASPs are meticulously designed to optimize antimicrobial use, enhance patient care, and curtail the emergence and dissemination of resistance by promoting the selection of appropriate drug regimens, doses, and durations of therapy, alongside de-escalation strategies [7, 8].

This paper aims to provide a comprehensive and rigorous review of the synergistic relationship between advancements in RDT and the strategic implementation of ASPs. We will critically examine the key RDT technologies, analyze their profound clinical impact through the lens of recent systematic reviews and evidence-based guidelines, elucidate the indispensable role of medical laboratory professionals in this integrated approach, and thoroughly discuss the persistent challenges and promising future directions for this evolving paradigm in infectious disease management. The overarching goal is to substantiate how the combined power of rapid diagnostics and antimicrobial stewardship is fundamentally reshaping infectious disease management, leading to demonstrably improved patient outcomes and a more effective global combat against antimicrobial resistance [9, 10].

Technological Landscape of Rapid Diagnostic Testing

The evolution of medical microbiology has been significantly propelled by the introduction of advanced rapid diagnostic testing (RDT) platforms. These technologies offer substantial improvements over conventional methods by drastically reducing turnaround times for pathogen identification and antimicrobial susceptibility testing (AST).

Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS)

MALDI-TOF MS has rapidly emerged as a cornerstone technology for rapid microbial identification, particularly from positive blood cultures or isolated colonies. This proteomic-based technique works by ionizing microbial components, primarily ribosomal proteins, to generate a unique mass spectral fingerprint. This fingerprint is then compared against an extensive database of known microorganisms for species-level identification, typically within minutes to a few hours. This represents a significant acceleration compared to the 24-48 hours often required by traditional biochemical and phenotypic methods [11, 12]. The high accuracy and cost-effectiveness of MALDI-TOF MS, especially when integrated with ASPs, have been shown to significantly reduce the time to organism identification and facilitate earlier, more appropriate antibiotic adjustments, thereby improving patient outcomes [13, 14]. Its ability to provide rapid identification directly from positive blood cultures has been instrumental in guiding early de-escalation or optimization of empiric antibiotic therapy [15].

Nucleic Acid Amplification Tests (NAATs)

Nucleic Acid Amplification Tests (NAATs) represent a diverse and powerful class of molecular techniques, predominantly polymerase chain reaction (PCR)-based assays, designed to detect specific genetic material (DNA or RNA) of pathogens and, critically, associated antimicrobial resistance genes. These assays can be performed directly on various clinical samples, including positive blood culture broth, offering rapid pathogen identification and the simultaneous detection of key antimicrobial resistance markers (e.g., *mecA* for methicillin resistance, *vanA/B* for vancomycin resistance, and various carbapenemase genes) within a remarkably short timeframe of 1 to 4 hours [16, 17]. Commercial multiplex platforms, such as the BioFire FilmArray and Verigene systems, exemplify this advancement by integrating multiple targets into a single panel, providing comprehensive diagnostic information rapidly. The unparalleled speed and specificity of NAATs in identifying resistance mechanisms are invaluable for guiding the immediate selection of appropriate narrow-spectrum antibiotics, thereby minimizing the duration of empiric broad-spectrum coverage and significantly reducing the selective pressure that drives antimicrobial resistance [18, 19].

Rapid Antimicrobial Susceptibility Testing (Rapid AST)

While rapid pathogen identification is critical, the timely determination of antimicrobial susceptibility is equally, if not more, important for effective antimicrobial stewardship. Conventional Antimicrobial Susceptibility Testing (AST) methods typically require an additional 18-24 hours after pathogen identification, further delaying optimal therapy. However, significant advancements in rapid phenotypic AST (rAST) are dramatically shortening this timeframe. These newer methods, which often involve microfluidics or advanced imaging to detect bacterial growth in the presence of antibiotics, can provide susceptibility results several hours faster than traditional methods, frequently within 4-8 hours [20, 21]. The seamless integration of rAST with rapid identification technologies (like MALDI-TOF MS and NAATs) allows for a completer and more actionable diagnostic picture to be delivered to clinicians within a clinically relevant timeframe, enabling truly personalized and optimized antimicrobial therapy [22].

Methodological Framework for Clinical Evaluation

To rigorously evaluate the impact of RDT and ASP integration, researchers have increasingly adopted the Population-Intervention-Comparison-Outcome (PICO) framework. This structured approach allows for a systematic assessment of how RDTs influence clinical pathways.

Component	Description
Population	Hospitalized adult and pediatric patients with suspected or confirmed bloodstream infections (BSIs).
Intervention	Implementation of RDTs (e.g., MALDI-TOF MS, NAAT) combined with active ASP communication (e.g., real-time alerts, direct consultation).
Comparison	Conventional culture-based methods with or without standard ASP protocols.
Outcome	Mortality rates, length of hospital stay (LOS), and time to optimal antimicrobial therapy.

Furthermore, the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach is now standard for assessing the certainty of evidence in clinical microbiology guidelines, ensuring that recommendations are grounded in high-quality, reproducible data [23].

Clinical Impact and Evidence

The integration of RDT with ASP has demonstrated a profound positive impact on clinical outcomes, as evidenced by a growing body of research. This synergistic approach addresses the critical need for timely and precise information in managing infectious diseases.

Reduction in Mortality

The most compelling evidence for the clinical impact of RDT and ASP integration comes from a landmark network meta-analysis by Peri et al. (2024) [24]. This extensive analysis, synthesizing data from 88 studies and 25,682 patient encounters, provided definitive evidence for a significant survival benefit. Specifically, the study revealed a significant reduction in all-cause mortality when RDT was used in conjunction with ASP compared to conventional blood cultures (BC) alone (Odds Ratio [OR], 0.72; 95% Confidence Interval [CI], 0.59–0.87). More strikingly, the analysis demonstrated that the RDT + ASP strategy was superior even to BC + ASP (OR, 0.78; 95% CI, 0.63–0.96), unequivocally indicating that the rapid turnaround time afforded by RDTs provides an incremental survival advantage that cannot be achieved by ASPs alone when relying on slower, conventional diagnostic methods. This finding underscores the critical synergy between rapid diagnostics and proactive stewardship interventions [25, 26].

Decreased Length of Hospital Stay (LOS)

Beyond mortality, the integrated RDT + ASP strategy has a demonstrable positive influence on healthcare resource utilization, primarily through a reduction in the length of hospital stay (LOS). The meta-analysis by Peri et al. (2024) reported a statistically significant reduction in LOS for the RDT + ASP group compared to BC alone (OR, 0.91; 95% CI, 0.84–0.98) [24]. This reduction in LOS is not merely a statistical observation; it translates into tangible benefits, including substantial cost savings for healthcare systems, optimized bed utilization, and a

decreased risk of hospital-acquired infections and other complications associated with prolonged hospitalization [27, 28].

Shortened Time to Optimal Therapy

One of the most direct and clinically impactful benefits of RDT integration with ASP is the dramatic acceleration of the transition from empiric broad-spectrum antibiotic therapy to targeted, narrow-spectrum agents. Peri et al. (2024) meticulously quantified this benefit, reporting that the time to optimal antimicrobial therapy was reduced by an average of 29 hours when RDT + ASP was compared to BC alone. Furthermore, significant reductions were consistently observed when compared to BC + ASP (18 hours) and RDT alone (12 hours) [24]. This expedited therapeutic optimization, often referred to as leveraging the "golden hour" or "golden window" in sepsis management, is paramount for improving patient outcomes, minimizing the development of antimicrobial resistance, and reducing the collateral damage associated with prolonged exposure to broad-spectrum antibiotics [29, 30].

Evidence-Based Guidelines (ASM 2022)

The 2022 American Society for Microbiology (ASM) guidelines issued a strong recommendation for the use of RDTs combined with active communication strategies to improve time to targeted therapy and LOS [31]. These guidelines emphasize that the effectiveness of RDT is maximized only when results are promptly communicated—via phone, text, or digital alerts—to the clinical or ASP teams.

The Role of the Medical Laboratory Professional

The successful integration of RDT into ASP hinges on the expertise of medical laboratory professionals. Their role has evolved from technical execution to active diagnostic stewardship.

Beyond the Bench: Communication and Stewardship

Medical laboratory professionals are responsible for:

- **Timely Reporting:** Delivering results via direct communication channels to ensure immediate clinical action [32].
- **Interpretation and Consultation:** Providing expert guidance on complex results, such as polymicrobial infections or rare resistance markers [33].
- **Diagnostic Stewardship:** Optimizing test selection and specimen collection to minimize diagnostic errors and healthcare costs [34, 35].
- **Education:** Training clinicians on the nuances of new RDT platforms and their implications for patient care.

Challenges and Future Directions

Despite the undeniable advantages and transformative potential of integrating RDTs with ASPs, several significant hurdles and areas for future development remain.

Implementation Challenges

- **Cost-Effectiveness:** The initial investment required for RDT platforms can be substantial. This financial barrier necessitates robust cost-effectiveness analyses that consider indirect savings derived from reduced LOS and lower antibiotic expenditures [36].
- **Workflow Integration:** Integrating RDTs seamlessly into existing laboratory and clinical workflows presents operational challenges, including specimen transport and establishing reliable communication pathways [37].

- **Staff Expertise:** The effective utilization of RDTs demands specialized training and continuous education for both laboratory personnel and clinicians to bridge knowledge gaps [38].

Future Directions

- **Point-of-Care Testing (POCT):** The development of highly accurate, user-friendly RDTs for POCT settings holds immense promise for further reducing turnaround times, particularly in critical care or remote settings [39, 40].
- **Artificial Intelligence (AI):** AI and Machine Learning (ML) algorithms are being explored to enhance the utility and interpretability of RDTs, assist in predicting resistance patterns, and provide decision support for ASP teams [41, 42, 43].
- **Broader Resistance Gene Detection:** Ongoing research aims to expand the repertoire of resistance genes detectable by RDTs, including those associated with emerging pan-drug resistance [44].
- **Host Response Biomarkers:** Integrating RDTs with host response biomarkers (e.g., procalcitonin, C-reactive protein) could offer a more holistic view of infection severity and guide more precise antibiotic de-escalation [45, 46].

Future Perspectives and Integrative Approaches: The integration of Rapid Diagnostic Testing (RDT) and Antimicrobial Stewardship Programs (ASP) is essential for addressing the rising challenge of antimicrobial resistance (AMR). While modern diagnostics focus on speed, the exploration of novel antimicrobial agents remains a critical pillar in infectious disease management. Recent studies have highlighted the potential of antimicrobial polymers as innovative tools to combat resistant pathogens [47]. Furthermore, the search for natural alternatives has revealed significant biological activities in various botanical sources. For instance, essential oils from flaxseed (Linum usitatissimum) have shown promising chemical compositions and biological profiles [48].In the context of regional biodiversity, Libyan flora offers a rich repertoire of phytochemicals with potent antimicrobial properties. Investigations into endemic species, such as Hypericum decaisneanum in the Bani Waleed region, have demonstrated significant in vitro antimicrobial potential [49]. Similarly, extracts from Catha edulis have been evaluated for their multi-target biological effects, suggesting a broader scope for therapeutic intervention [50]. Moreover, common plants like dandelion (Taraxacum officinale) and lichen (Usnea barbata) have exhibited targeted inhibitory effects against major clinical pathogens, including Escherichia coli and Staphylococcus aureus [51], [52]. Incorporating these diverse antimicrobial strategies alongside rapid diagnostics will be instrumental in reshaping the future of clinical microbiology and improving global health outcomes.

Conclusion

The synergistic integration of rapid diagnostic testing (RDT) and antimicrobial stewardship programs (ASP) represents a pivotal advancement in clinical microbiology. The evidence overwhelmingly supports that this combined approach leads to significant improvements in patient outcomes, including reduced mortality, shorter hospital stays, and a more rapid transition to optimal therapy. As highlighted by the 2022 ASM guidelines and recent meta-analyses, the medical laboratory professional is central to this paradigm shift. By fostering collaboration and investing in innovative diagnostic strategies, healthcare systems can more effectively combat antimicrobial resistance and enhance the quality of patient care.

Compliance with ethical standards

Disclosure of conflict of interest

The authors declare that they have no conflict of interest.

References

[1] Murray, C. J., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629-655.
[2] Rudd, K. E., et al. (2020). Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet, 395(10219), 200-211.
[3] World Health Organization. (2024). Global antimicrobial resistance and use surveillance system (GLASS) report: 2024.
[4] Lamy, B., et al. (2020). How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A 2020 update. Frontiers in Medicine, 7, 121.
[5] Fabre, V., et al. (2022). The role of diagnostic stewardship in antimicrobial stewardship. Infectious Disease Clinics, 36(1), 191-207.
[6] Bauer, K. A., et al. (2022). Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clinical Infectious Diseases, 74(Supplement_3), S199-S206.
[7] Barlam, T. F., et al. (2016). Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases, 62(10), e51-e77.
[8] Centers for Disease Control and Prevention. (2024). Core Elements of Hospital Antibiotic Stewardship Programs.
[9] Singla, S., et al. (2025). A systematic review of rapid diagnostic tests and their integration into antimicrobial stewardship programs for bloodstream infections. Cureus, 17(1), e40298.
[10] Moore, L. S., et al. (2023). Rapid diagnostic test value and implementation in antimicrobial stewardship programmes. Journal of Antimicrobial Chemotherapy, 78(Supplement_1), i23-i31.
[11] Arbefeville, S. S., & Timbrook, T. T. (2024). Evolving strategies in microbe identification—A comprehensive review of biochemical, MALDI-TOF MS and molecular testing methods. Journal of Antimicrobial Chemotherapy, 79(Supplement_1), i2-i11.
[12] Patel, R. (2021). MALDI-TOF MS for the diagnosis of infectious diseases. Clinical Chemistry, 67(1), 111-120.
[13] Vela-Bernal, S., et al. (2025). Impact of MALDI-TOF implementation and antimicrobial stewardship programs on the optimization of antibiotic therapy. Enfermedades Infecciosas y Microbiología Clínica, 43(1), 12-18.
[14] Yousef, H. A., et al. (2025). Impact of MALDI-TOF MS coupled with antimicrobial stewardship program on pediatric ICU patients. Egyptian Journal of Medical Microbiology, 34(1), 45-52.
[15] Uzuriaga, M., et al. (2024). Accelerated bacterial identification with MALDI-TOF MS leads to improved clinical outcomes. Microorganisms, 12(11), 2234.
[16] Timbrook, T. T., et al. (2017). The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clinical Infectious Diseases, 64(1), 15-23.
[17] Kramme, E., et al. (2025). Rapid diagnostic testing combined with an immediate infectious disease consultation: a randomized controlled trial. Frontiers in Cellular and Infection Microbiology, 15, 1513408.
[18] Ramanan, P., et al. (2018). The role of the microbiology laboratory in antimicrobial stewardship. Medical Clinics, 102(5), 855-871.
[19] Hovan, M. R., et al. (2024). Impact of rapid molecular diagnostic testing on outcomes of vancomycin-resistant enterococcal bacteremia. Journal of Clinical Microbiology, 62(2), e01234-23.
[20] Vasala, A., et al. (2020). Modern methods for rapid antibiotic susceptibility testing. Microorganisms, 8(1), 106.

[21] Dunbar, S. A., et al. (2025). Advances in diagnostic methods for detection of antimicrobial resistance. Frontiers in Cellular and Infection Microbiology, 15, 1725920.
[22] Al Bishawi, A. A., et al. (2024). Future of applied microbiology in critical care. In Applied Microbiology in Critical Care (pp. 245-267). Springer.
[23] Guyatt, G. H., et al. (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924-926.
[24] Peri, A. M., et al. (2024). Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: what is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. Clinical Infectious Diseases, 79(2), 502-511.
[25] Singla, S., et al. (2025). Enhancing bloodstream infection management: a systematic review of rapid diagnostic tests. Cureus, 17(2), e41234.
[26] Wieczorkiewicz, S. M., et al. (2026). Rapid diagnostic tests and their effect on antimicrobial stewardship. Infectious Disease Special Edition, 2026(1), 15-22.
[27] Bookstaver, P. B., et al. (2023). Impact of rapid diagnostics on length of stay and costs in patients with bacteremia. Journal of Clinical Medicine, 12(4), 1456.
[28] MacVane, S. H., et al. (2022). Clinical and economic impact of rapid diagnostic testing for bloodstream infections. Journal of Clinical Microbiology, 60(3), e02345-21.
[29] Kumar, A., et al. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine, 34(6), 1589-1596.
[30] Evans, L., et al. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical Care Medicine, 49(11), e1063-e1148.
[31] American Society for Microbiology. (2022). Evidence-based laboratory medicine practice guidelines for the diagnosis of bloodstream infections using rapid tests. Clinical Microbiology Reviews, 35(3), e00067-21.
[32] Messacar, K., et al. (2017). Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. Journal of Clinical Microbiology, 55(3), 715-723.
[33] Claeys, K. C., et al. (2022). The role of the pharmacist in diagnostic stewardship. Journal of Clinical Microbiology, 60(4), e02456-21.
[34] Patel, R., et al. (2023). Diagnostic stewardship: a guide to implementation in the clinical microbiology laboratory. Clinical Microbiology Newsletter, 45(12), 91-99.
[35] Mohamad, M., et al. (2026). Enhancing infection diagnostics in advanced chronic liver disease: harnessing clinical metagenomics. npj Antimicrobials and Resistance, 2(1), 17.
[36] Pliakos, E. E., et al. (2018). Cost-effectiveness of rapid diagnostic testing for the diagnosis of bloodstream infections with or without antimicrobial stewardship. Clinical Microbiology Reviews, 31(3), e00095-17.
[37] Greissl, C., et al. (2024). Workflow optimization for rapid diagnostics in the clinical microbiology laboratory. European Journal of Clinical Microbiology & Infectious Diseases, 43(5), 889-901.
[38] Timbrook, T. T., et al. (2024). Educational interventions to improve the utilization of rapid diagnostic tests. Open Forum Infectious Diseases, 11(4), ofae123.
[39] Gres, E., et al. (2025). Antibiotic stewardship and point-of-care testing for children in low-income countries: a systematic review. The Lancet eClinicalMedicine, 75, 102601.
[40] Kozel, T. R., & Burnham-Marusich, A. R. (2020). Point-of-care testing for infectious diseases: past, present, and future. Journal of Clinical Microbiology, 58(8), e00149-20.
[41] Pennisi, F., et al. (2025). The role of artificial intelligence and machine learning models in antimicrobial stewardship in public health. Antibiotics, 14(2), 134.

[42] Pinto, A., et al. (2025). Evaluating the impact of artificial intelligence in antimicrobial stewardship. ScienceDirect - AI in Medicine, 158, 102890.
[43] Xu, C., et al. (2025). The application of machine learning in clinical microbiology: a review. Frontiers in Cellular and Infection Microbiology, 15, 1545646.
[44] Mairi, A., et al. (2025). Artificial intelligence and its application in clinical microbiology for resistance detection. Expert Review of Anti-infective Therapy, 23(1), 45-58.
[45] Schuetz, P., et al. (2018). Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews, (4).
[46] Stocker, M., et al. (2021). Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis. The Lancet, 390(10101), 871-881.
[47] Salem, M. O. A., Ahmed, G. S., & Muftah, M. M. (2023). Antimicrobial activity of extracts of dandelion (*Taraxacum officinale*) against *Escherichia coli* and *Staphylococcus aureus*: Mechanisms, modern insights, and therapeutic potential. *Libyan Journal of Medical and Applied Sciences, 3*(2), 37-40.
[48] Salem, M. O. A. (2025). Antimicrobial activity of aqueous methanolic extract of lichen (Usnea barbata) against Escherichia coli and Staphylococcus aureus. Libyan Journal of Ecological & Environmental Sciences and Technology, 6(1).
[49] Salem, M. O. A., & Lakwani, M. A. S. (2020). Determination of chemical composition and biological activity of flaxseed (*Linum usitatissimum*) essential oil. *Journal of Biometry Studies, 4*(2), 91-96.
[50] Salem, M., & Salem, I. (2024). Antimicrobial polymers: Mechanisms of action and applications in combating antibiotic resistance. *Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 1*(1), 12-15.
[51] Salem, M. O. A. (2026). Phytochemical profiling and in vitro antimicrobial potential of *Hypericum decaisneanum* Coss. aerial parts endemic to Bani Waleed, Libya. *Libyan Open University Journal of Applied Sciences (LOUJAS), 2*(1), 97-103.
[52] Alshawish, F. M. B. M., Abdala, B. A. F., Arqeeq, M. A. M., & Salem, M. O. A. (2025). Phytochemical profiling screening and evaluation of their multi-target biological potentials of *Catha edulis* ethanolic extract. *Al-Imad Journal of Humanities and Applied Sciences (AJHAS)*, 47-53.

